The advent of anti-vascular endothelial growth has massively resulted in reducing the vision loss caused by neovascular age-related macular degeneration (n-AMD).
The response of the anti-VEGF therapy relies on various factors such as the patient’s lesion characteristics, age, lesion duration, baseline visual acuity, and various genotype risk alleles.
In addition, individuals affected with n-AMD result in decreasing morphology or acuity, even after therapy, or it may need frequent re-treatment.
Vascular endothelial growth factor involves numerous pathological processes. It is widely utilized in the R&D of various illness therapies.
The anti-VEGF therapeutics industry has generated $12,178.0 million revenue in 2021, and it is projected to generate $13,812.6 million revenue, advancing at a rate of 1.4% from 2021 to 2030. It is widely influenced by FDA approvals for products in the pipeline, including R&D activities in the field.
VEGF results in the development of diabetic retinopathy, and age-related macular degeneration in wet form. Therefore, anti-VEGF is crucial for the treatment of such conditions.
Moreover, the rising prevalence of ophthalmic diseases such as AMD, macular edoema, DR, and retinal vein occlusion, due to the increasing elderly population propels the risk of developing various diseases. It leads to increased demand for anti-VEGF therapeutics to treat such conditions.
On average, people aged 50 years or more are more likely to get blind due to rising incidences of AMD. More than 6.22 million people are more likely to be affected by moderate-to-sever vision impairment. Furthermore, the rising adoption of anti-VEGF medications has resulted in reduced incidences of AMD blindness by 20% from 2000 to 2020.
